Jillian J. Kril

Jillian J. Kril

Auto-generated profile, based on publicly available information

Jillian J. Kril

Discipline of Pathology, Sydney Medical School, The University of Sydney, Australia

Research Focus & Metrics

Academic Career Length

43Years (1984-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 November 2009 in Acta Neuropathologica
Verified
Journal Article
Open access
PDF file
IMIan R. A. Mackenzie
Ian R. A. Mackenzie
MNManuela Neumann
Manuela Neumann
EBEileen H. Bigio
Eileen H. Bigio
NCNigel J. Cairns
Nigel J. Cairns
IAIrina Alafuzoff
Irina Alafuzoff
DMDavid M. A. Mann
David M. A. Mann

14 February 2010 in Nature Genetics
Verified
Journal Article
Open access
PDF file
VDVivianna M Van Deerlin
Vivianna M Van Deerlin
PSPatrick M A Sleiman
Patrick M A Sleiman
MMMaria Martinez-Lage
Maria Martinez-Lage
ACAlice Chen-Plotkin
Alice Chen-Plotkin
LWLi-San Wang
Li-San Wang
VLVirginia M-Y Lee
Virginia M-Y Lee
Vivianna Van Deerlin and colleagues report that common variants at 7p21 are associated with a subtype of frontotemporal lobar degeneration marked by TDP-43 inclusions. They further show that the risk alleles are associated with elevated brain expression of TMEM106B, which resides at the peak of association on 7p21. Frontotemporal lobar degeneration (FTLD) is the second most common cause of presenile dementia. The predominant neuropathology is FTLD with TAR DNA-binding protein (TDP-43) inclusions (FTLD-TDP)1. FTLD-TDP is frequently familial, resulting from mutations in GRN (which encodes progranulin). We assembled an international collaboration to identify susceptibility loci for FTLD-TDP through a genome-wide association study of 515 individuals with FTLD-TDP. We found that FTLD-TDP associates with multiple SNPs mapping to a single linkage disequilibrium block on 7p21 that contains TMEM106B. Three SNPs retained genome-wide significance following Bonferroni correction (top SNP rs1990622, P = 1.08 × 10−11; odds ratio, minor allele (C) 0.61, 95% CI 0.53–0.71). The association replicated in 89 FTLD-TDP cases (rs1990622; P = 2 × 10−4). TMEM106B variants may confer risk of FTLD-TDP by increasing TMEM106B expression. TMEM106B variants also contribute to genetic risk for FTLD-TDP in individuals with mutations in GRN. Our data implicate variants in TMEM106B as a strong risk factor for FTLD-TDP, suggesting an underlying pathogenic mechanism.

31 August 2004 in Annals of Neurology
Verified
Journal Article
Closed access
PDF file
JHJohn R. Hodges
John R. Hodges
RDR. Rhys Davies
R. Rhys Davies
JXJohn H. Xuereb
John H. Xuereb
BCBarney Casey
Barney Casey
MBMelissa Broe
Melissa Broe
GHGlenda M. Halliday
Glenda M. Halliday

10 December 2015 in Acta Neuropathologica
Verified
Journal Article
Open access
PDF file
Gabor G. KovacsGabor G. Kovacs
Gabor G. Kovacs
IFIsidro Ferrer
Isidro Ferrer
LGLea T. Grinberg
Lea T. Grinberg
IAIrina Alafuzoff
Irina Alafuzoff
JAJohannes Attems
Johannes Attems
DDDennis W. Dickson
Dennis W. Dickson
Pathological accumulation of abnormally phosphorylated tau protein in astrocytes is a frequent, but poorly characterized feature of the aging brain. Its etiology is uncertain, but its presence is sufficiently ubiquitous to merit further characterization and classification, which may stimulate clinicopathological studies and research into its pathobiology. This paper aims to harmonize evaluation and nomenclature of aging-related tau astrogliopathy (ARTAG), a term that refers to a morphological spectrum of astroglial pathology detected by tau immunohistochemistry, especially with phosphorylation-dependent and 4R isoform-specific antibodies. ARTAG occurs mainly, but not exclusively, in individuals over 60 years of age. Tau-immunoreactive astrocytes in ARTAG include thorn-shaped astrocytes at the glia limitans and in white matter, as well as solitary or clustered astrocytes with perinuclear cytoplasmic tau immunoreactivity that extends into the astroglial processes as fine fibrillar or granular immunopositivity, typically in gray matter. Various forms of ARTAG may coexist in the same brain and might reflect different pathogenic processes. Based on morphology and anatomical distribution, ARTAG can be distinguished from primary tauopathies, but may be concurrent with primary tauopathies or other disorders. We recommend four steps for evaluation of ARTAG: (1) identification of five types based on the location of either morphologies of tau astrogliopathy: subpial, subependymal, perivascular, white matter, gray matter; (2) documentation of the regional involvement: medial temporal lobe, lobar (frontal, parietal, occipital, lateral temporal), subcortical, brainstem; (3) documentation of the severity of tau astrogliopathy; and (4) description of subregional involvement. Some types of ARTAG may underlie neurological symptoms; however, the clinical significance of ARTAG is currently uncertain and awaits further studies. The goal of this proposal is to raise awareness of astroglial tau pathology in the aged brain, facilitating communication among neuropathologists and researchers, and informing interpretation of clinical biomarkers and imaging studies that focus on tau-related indicators.

1 June 1997 in Neuroscience
Verified
Journal Article
Closed access
JKJ.J Kril
J.J Kril
GHG.M Halliday
G.M Halliday
MSM.D Svoboda
M.D Svoboda
HCH Cartwright
H Cartwright

27 December 2013 in Acta Neuropathologica
Verified
Journal Article
Closed access
PDF file
SMSuzanne M de la Monte
Suzanne M de la Monte
JKJillian J. Kril
Jillian J. Kril